z-logo
open-access-imgOpen Access
Immediate and transient phosphorylation of the heat shock protein 27 initiates chemoresistance in prostate cancer cells
Author(s) -
Matthias B. Stope,
Martin Weiß,
Melanie Preuß,
Andreas Streitbörger,
Christoph A. Ritter,
Uwe Zimmermann,
Reinhard Walther,
Martin Burchardt
Publication year - 2014
Publication title -
oncology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.094
H-Index - 96
eISSN - 1791-2431
pISSN - 1021-335X
DOI - 10.3892/or.2014.3492
Subject(s) - hsp27 , docetaxel , phosphorylation , heat shock protein , cancer research , dephosphorylation , p38 mitogen activated protein kinases , protein kinase a , cancer cell , cancer , kinase , prostate cancer , biology , protein phosphorylation , mapk/erk pathway , microbiology and biotechnology , medicine , hsp70 , biochemistry , phosphatase , gene
Drug resistance minimizes the effects of prostate cancer (PC) chemotherapy with docetaxel and is generally considered to be associated with the expression of heat shock protein (HSP) 27 including various cytoprotective pathways. In the present study, we investigated the effects of HSP27 phosphorylation on PC cell growth underlying docetaxel treatment. Cell counting revealed significantly reduced cell growth during docetaxel treatment as a result of both activation of mitogen-activated protein kinase p38 (MAPK p38) and protein kinase D1 (PKD1), and, most importantly, the overexpression of the phosphorylation-mimicking mutant HSP27-3D. Further analysis revealed a docetaxel-dependent induction of HSP27 accompanied by an initial phosphorylation and rapid dephosphorylation of the protein. Based on the data, we can conclude that phosphorylation of HSP27 protein is a crucial mechanism in the initiation of chemoresistance in PC. Moreover, the results indicate a key impact of HSP27 on viability and proliferation of PC cells underlying anticancer therapy. The protective function depends on the initial phosphorylation status of HSP27 and represents a putative co-therapeutic target to prevent chemoresistance during docetaxel therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom